Maikeoute Passes HKEX Hearing, Core Product MT1013 Enters Phase III Clinical Trial
N.R. Finch
Mecaution passed its HKEX main-board listing hearing on June 4, with its dual-target peptide drug MT1013 now in a Phase III trial — all 424 planned patients enrolled — marking a pivotal step for the pre-revenue biotech's Hong Kong IPO.
What does this company do?
Mecaution (麦科奥特) focuses on metabolic and cardiovascular diseases, building dual- and multi-specific peptide drugs — synthetic peptide chains engineered to hit two targets at once instead of the traditional one-drug-one-target approach.
Its only late-stage asset is MT1013, a peptide that simultaneously activates both the CaSR and OGP receptors. The target disease is CKD-SHPT — chronic kidney disease-secondary hyperparathyroidism, a condition where declining kidney function pushes parathyroid hormone abnormally high, driving bone disease and cardiovascular risk.
This means → Mecaution is a classic single-pipeline, pre-commercial biotech. Its entire valuation rests on MT1013 alone.
What did the Phase II data show?
In a head-to-head comparison, MT1013's combined iPTH, calcium, and phosphorus target-attainment rate was roughly 2.5× higher than approved CaSR agonist etelcalcetide.
The drug took effect within three weeks and sustained iPTH control through week nine; no severe hypocalcemia was reported across trials.
MT1013 was also linked to a greater reduction in FGF23 — a biomarker directly tied to cardiovascular risk in CKD-SHPT — and showed potential to improve bone turnover and metabolism.
In plain terms = early data point to better efficacy and a clean safety profile versus existing drugs, but the prospectus explicitly cautions this is early-stage evidence, not conclusive.
Where does the Phase III trial stand?
The Phase III trial uses cinacalcet (a current standard-of-care drug) as an active comparator. All 424 planned patients have completed enrollment.
This means → enrollment is one of the most time-consuming steps in Phase III; the next milestone is treatment-period completion and data readout.
Phase III results will determine whether MT1013 can file for approval — for a single-pipeline biotech, this is an all-or-nothing validation event.
How large is the market?
Per the prospectus: China's CKD-SHPT drug market is projected to reach RMB 5 billion by 2030 and RMB 13.1 billion by 2035, a CAGR of 21.4%.
Global CKD-SHPT patients number roughly 160.4 million (2025), expected to reach 188 million by 2030.
This reflects a large-base, steadily growing therapeutic area — but how much share Mecaution captures depends entirely on Phase III data and commercial execution.
What do the finances look like?
Other income totaled RMB 4.002 million (2024) and RMB 2.301 million (2025); net losses were approximately RMB 157 million and RMB 185 million respectively — losses continue to widen.
In plain terms = the company has virtually no operating revenue; cash goes to clinical trials. Widening losses are normal for R&D-stage biotechs, but they also mean IPO fundraising is a survival necessity.
CMBI and China Merchants Securities International serve as joint sponsors. With the hearing cleared, the next step is book-building and pricing.
Content is for reference only, not financial advice.